what science actually says about bpc 157 benefits Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing Peptide BPC-157 - Does It

A., & Miasoedov, N

[9] In September 2008, the FDA granted approval as a first-line treatment, in combination with cisplatin, against locally advanced and metastatic non-small cell lung cancer (NSCLC) in patients with non-squamous histology

However, no significant change in p-JNK protein level was observed in HUVECs (Figure 6)

The standard regimen is 1 mg administered three times weekly for two weeks (or on alternate days for six doses if neurological symptoms are present), followed by maintenance doses every two to three months

Once your B12 levels have stabilised, continuing injections every few weeks or months can help maintain their positive effects, ensuring energy levels and overall health remain consistent